Metabolic Inflammation in Obesity and NAFLD: Pathological Basis and Emerging Pharmacologic Interventions

Abstract

Aims: To review the pathological basis of metabolic inflammation in obesity and non-alcoholic fatty liver disease (NAFLD) and to evaluate emerging pharmacologic interventions targeting inflammatory and metabolic pathways. Study Design: Narrative review of contemporary biomedical literature. Methodology: Peer-reviewed literature from major biomedical databases (PubMed, MEDLINE, Scopus, Web of Science) was analyzed, focusing on adipose tissue histopathology, cytokine-mediated insulin resistance, NAFLD progression, and clinical trials involving GLP-1 receptor agonists, SGLT2 inhibitors, and emerging dual incretin therapies. Landmark studies and high-impact publications from 2000 to 2024 were prioritized. Results: Obesity is characterized by adipocyte hypertrophy, macrophage infiltration, and formation of crown-like structures within adipose tissue. Pro-inflammatory cytokines such as TNF-α and IL-6 disrupt insulin signaling pathways and promote systemic metabolic dysfunction through NF-κB and JNK pathway activation. In the liver, chronic inflammatory activation contributes to steatosis, hepatocyte ballooning, and progressive fibrosis orchestrated by activated hepatic stellate cells. Pharmacologic agents including GLP-1 receptor agonists, SGLT2 inhibitors, and dual incretin agonists demonstrate metabolic and anti-inflammatory benefits, with histological improvement in steatosis and fibrosis observed in clinical trials. Emerging therapies targeting nuclear receptors, PPAR pathways, and gut microbiota-mediated inflammation represent promising next-generation strategies. Emerging non-invasive biomarkers and precision medicine approaches are improving early detection and therapeutic stratification in metabolic inflammatory diseases. Conclusion: Metabolic inflammation is a central therapeutic target in obesity and NAFLD. Integration of pathological insights with pharmacologic innovation supports precision metabolic medicine and interdisciplinary translational approaches. Given the rapidly increasing global prevalence of obesity and NAFLD, understanding metabolic inflammation has important clinical implications for developing targeted therapies and guiding precision metabolic medicine strategies.